Clinical Study of CAR-iNKT Cells in the Treatment of Relapsed/Refractory/High-risk B-cell Tumors
Status:
Recruiting
Trial end date:
2024-04-01
Target enrollment:
Participant gender:
Summary
This study aims to evaluate the safety and feasibility of hCD19.IL15.CAR-iNKT cells in
treating patients with relapsed/refractory/high-risk B-cell tumors.
Phase:
Phase 1
Details
Lead Sponsor:
Kai Lin Xu; Jun Nian Zheng
Collaborators:
Affiliated Hospital of Jiangsu University First Affiliated Hospital of Zhejiang University Huai 'an First People's Hospital Nantong University North Jiangsu People's Hospital The First People's Hospital of Changzhou